CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Option exercise | +20,312 | $9.30 | $189K | 109,814 |
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Option exercise | +57,812 | $10.05 | $581K | 167,626 |
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Sale | −114,240 | $16.25 | $1.9M | 53,386 |
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −24,356 | 0 | ||
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −20,312 | 4,688 | ||
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −57,812 | 17,188 | ||
| 2021-03-05 | Anicetti Vincent R Chief Operating Officer | Option exercise | +20,312 | $9.30 | $189K | 80,051 |
| 2021-03-05 | Anicetti Vincent R Chief Operating Officer | Sale | −20,312 | $15.46 | $314K | 59,739 |
| 2021-03-05 | Anicetti Vincent R Chief Operating Officer | Sale | −6,337 | $15.46 | $98K | 53,402 |
| 2021-03-05 | Anicetti Vincent R Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −20,312 | 4,688 | ||
| 2021-02-17 | Anicetti Vincent R Chief Operating Officer | Option exercise | +2,488 | $2.50 | $6K | 62,227 |
| 2021-02-17 | Anicetti Vincent R Chief Operating Officer | Sale | −2,488 | $17.45 | $43K | 59,739 |
| 2021-02-17 | Anicetti Vincent R Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −2,488 | 0 | ||
| 2021-02-01 | Vexler Vladimir Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2021-02-01 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2021-02-01 | Viret Jean-Frederic Chief Financial Officer | Option exercise | +7,402 | $10.05 | $74K | 68,697 |
| 2021-02-01 | Viret Jean-Frederic Chief Financial Officer | Sale | −7,402 | $21.55 | $160K | 61,295 |
| 2021-02-01 | Viret Jean-Frederic Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −7,402 | 54,167 | ||
| 2021-01-25 | Viret Jean-Frederic Chief Financial Officer | Option exercise | +40,000 | $10.05 | $402K | 107,439 |
| 2021-01-25 | Viret Jean-Frederic Chief Financial Officer | Sale | −40,000 | $20.10 | $804K | 67,439 |
Page 10 of 39 · 768 trades